Anthem Biosciences Limited has submitted to the Exchange, the outcome of the Board Meeting dated May 19, 2026 declaring the financial results for the quarter and the financial year ended March 31, 2026 along with other matters.
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences reported audited standalone revenue of ₹2,089 crore for FY26 (up 13.5% YoY) with PAT of ₹570.6 crore (up 12.7%). On a consolidated basis, revenue stood at ₹2,120 crore (up 14.9%) and PAT at ₹567.8 crore, up 25.8% YoY. The auditors (K.P. Rao & Co.) issued an unmodified opinion on both standalone and consolidated results. The Board recommended a final dividend of ₹2 per share (record date June 26, 2026) and approved ESOP allotments totalling 14,81,250 equity shares. An exceptional item of ₹240.13 million (standalone) / ₹243.91 million (consolidated) was recognised due to provisioning under new Indian Labour Codes. The wholly-owned subsidiary Neoanthem Lifesciences reported a net loss of ₹787.45 million for FY26. The company's net cash from operating activities was ₹889 crore (standalone).
Strong double-digit topline growth and 25.8% PAT growth on consolidated basis signal solid operational performance, though the subsidiary loss and exceptional labour code provisioning warrant monitoring. The unmodified audit opinion removes audit quality concerns.